June 8, 2022 — The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial involving SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, just one week ...
Drug-Eluting Balloons
This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.
-
-
May 27, 2022 — Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a ...
-
May 27, 2022 — The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent (DES). SELUTION SLR ...
-
May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD) study were presented as late-breaking clinical research ...
June 8, 2022 — The first patient has been enrolled in the FDA IDE BTK (Below-the-Knee) SELUTION4BTK clinical trial ...
June 08, 2022
May 27, 2022 — Medtronic today announced approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 ...
May 27, 2022
May 27, 2022 — The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a ...
May 27, 2022
May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel ...
May 20, 2022
May 19, 2022 — One year outcomes from the Disrupt PAD III Trial comparing intravascular lithotripsy (IVL) with a drug ...
May 19, 2022
March 31, 2022 — In accordance with its commitment to patient safety, Medtronic recently voluntarily recalled a subset ...
March 31, 2022
November 10, 2021 — Biosensors International Group Ltd., a developer and manufacturer of innovative medical devices ...
November 10, 2021
October 20, 2021 — 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a late-breaking ...
October 20, 2021
June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...
June 07, 2021
May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...
May 20, 2021
Feature | Balloon Catheter | By Dave Fornell, Editor
The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...
March 16, 2021
March 12, 2021 — Philips Healthcare announced the final, five-year results of two major randomized controlled trials ...
March 12, 2021
November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated ...
November 03, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...
October 18, 2020
October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the ...
October 18, 2020© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now